Medical News

RSS

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.

1 Oct 2015

New reference catalogue may help guide future studies of genetics, evolution and disease

Missing a gene may be less problematic than you'd think. This is one of the conclusions that emerge from the most extensive catalogue of structural variations - changes in large sections of a person's DNA sequence - to date.

1 Oct 2015

European Food Venture Forum held in Aarhus, Denmark

You probably don't think about it, but when you go to your local supermarket to buy e.g. yoghurt, huge efforts have been made to allow you to choose this particular product.

1 Oct 2015

Study shows antipsychotic medication increases death risk in patients with Parkinson's disease psychosis

Antipsychotic drugs may increase the risk of death in people with Parkinson's disease psychosis (PDP), according to a new study led by researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London.

1 Oct 2015

Bright Instruments unveiled new touch screen ‘OTF5500’ at IBMS Congress

Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.

1 Oct 2015

Beckman Coulter Life Sciences launches QbD1200 Total Organic Carbon (TOC) Analyzer

Beckman Coulter Life Sciences has launched the QbD1200 Total Organic Carbon (TOC) Analyzer.

From Beckman Coulter Life Sciences - Particle Counting and Characterization 1 Oct 2015

New RNA tools for CRISPR/Cas9

Integrated DNA Technologies (IDT) will host an informative webinar, entitled ‘New RNA Tools for Optimized CRISPR/Cas9 Genome Editing’, on Wednesday, October 7, 2015. Ashley Jacobi, a scientist in the Molecular Genetics Applied Research Group at IDT, and an expert in the application of synthetic nucleic acids, will present the webinar at 9 am and 1 pm Central Standard Time.

From Integrated DNA Technologies 1 Oct 2015

Orlando Health gets Overall 3 Star Rating for bypass surgery and lobectomy

Orlando Health received an Overall 3 Star Rating from The Society of Thoracic Surgeons for quality care provided to patients undergoing bypass surgery and lobectomy for lung cancer.

30 Sep 2015

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiveness after about one to two years, leading to recurrence and, ultimately, death. A University of Houston researcher and his team are working to change that.

30 Sep 2015

Cornell University, MSKCC jointly open new $10 million Center of Cancer Nanotechnology Excellence

Cornell University, in partnership with Memorial Sloan Kettering Cancer Center, is opening a new $10 million Center of Cancer Nanotechnology Excellence that brings together scientists, engineers, biologists and physicians to develop and translate new cancer care applications based on nanotechnology.

30 Sep 2015

Researchers roll out updated online breast cancer risk calculator

Growing up, Charlotte Gard knew she came from a long line of women who developed breast cancer. The New Mexico State University assistant professor always expected her mother to develop it, like her grandmother before her, so she knew she wanted to contribute to research that would help fight the disease that kills more than 40,000 women in the U.S. every year.

30 Sep 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Coalition unions, Kaiser Permanente sign landmark contract to protect health care workers and patients from flu

A coalition of unions representing Kaiser Permanente health care workers in the nation's largest private sector talks this year have ratified a landmark agreement that includes a jointly developed flu vaccination policy for health care workers who deal directly with patients.

30 Sep 2015

Generex agrees to acquire 51% equity interest in Hema Diagnostic Systems

Generex Biotechnology Corporation today announced that it has entered into a non-binding Letter of Intent (LOI) with Hema Diagnostic Systems, LLC (HDS), a Florida company that designs and manufactures proprietary infectious disease detection technologies.

30 Sep 2015

Unlocking the genes behind antibiotic resistance: an interview with Professor Romesberg

Bacteria are very, very diverse. This is why their susceptibility to different antibiotics can be very different. It also makes the tools they have to evolve resistance in many cases different.

30 Sep 2015

Catasys starts enrolling members in OnTrak Program

Catasys, Inc., a provider of proprietary big data based analytics and predictive modeling driven behavioral health management services for health plans, announced today that it has begun enrolling members in its OnTrak Program with Health Alliance Medical Plans (Health Alliance) in Illinois. In April, Catasys and Health Alliance announced a multi-year agreement for the OnTrak Program.

30 Sep 2015

Tunitas Therapeutics completes $10 million Series A venture financing

Tunitas Therapeutics, Inc. today announced the close of a $10 million Series A venture financing. The financing was co-led by Ally Bridge Group and WuXi Ventures, with the further participation of RA Capital Advisors.

30 Sep 2015

OncoGenex meets target enrollment in apatorsen Phase 2 trial

OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.

30 Sep 2015

BiondVax to begin Phase IIb clinical trial of universal influenza vaccine in Europe

BiondVax Pharmaceuticals Ltd. announced today that it received regulatory clearance from the Hungarian Regulatory Authority (National Institute of Pharmacology and Nutrition, OGYEI) and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial. The initiation meeting was scheduled for today, September 30, 2015, together with the partners from the UNISEC European Consortium.

30 Sep 2015

VA Hospital performs first successful heated chemotherapy bath on a patient with mesothelioma

Nationalmesotheliomaclaims.com, a comprehensive website that provides people with mesothelioma and their families with in-depth information and free resources about the disease, is excited to report that a VA Hospital in Roxbury, MA has just performed the first successful heated chemotherapy bath.

30 Sep 2015

Medical News

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

New reference catalogue may help guide future studies of genetics, evolution and disease

European Food Venture Forum held in Aarhus, Denmark

Study shows antipsychotic medication increases death risk in patients with Parkinson's disease psychosis

Bright Instruments unveiled new touch screen ‘OTF5500’ at IBMS Congress

Beckman Coulter Life Sciences launches QbD1200 Total Organic Carbon (TOC) Analyzer

New RNA tools for CRISPR/Cas9

Orlando Health gets Overall 3 Star Rating for bypass surgery and lobectomy

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Cornell University, MSKCC jointly open new $10 million Center of Cancer Nanotechnology Excellence

Researchers roll out updated online breast cancer risk calculator

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Coalition unions, Kaiser Permanente sign landmark contract to protect health care workers and patients from flu

Generex agrees to acquire 51% equity interest in Hema Diagnostic Systems

Unlocking the genes behind antibiotic resistance: an interview with Professor Romesberg

Catasys starts enrolling members in OnTrak Program

Tunitas Therapeutics completes $10 million Series A venture financing

OncoGenex meets target enrollment in apatorsen Phase 2 trial

BiondVax to begin Phase IIb clinical trial of universal influenza vaccine in Europe

VA Hospital performs first successful heated chemotherapy bath on a patient with mesothelioma

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Latest News